Bone grafting

Résumé

Bone grafting is a surgical procedure that replaces missing bone in order to repair bone fractures that are extremely complex, pose a significant health risk to the patient, or fail to heal properly. Some small or acute fractures can be cured without bone grafting, but the risk is greater for large fractures like compound fractures. Bone generally has the ability to regenerate completely but requires a very small fracture space or some sort of scaffold to do so. Bone grafts may be autologous (bone harvested from the patient's own body, often from the iliac crest), allograft (cadaveric bone usually obtained from a bone bank), or synthetic (often made of hydroxyapatite or other naturally occurring and biocompatible substances) with similar mechanical properties to bone. Most bone grafts are expected to be resorbed and replaced as the natural bone heals over a few months' time. The principles involved in successful bone grafts include osteoconduction (guiding the reparative growth of

Source officielle

https://en.wikipedia.org/wiki/Bone_grafting

À propos de ce résultat

Cette page est générée automatiquement et peut contenir des informations qui ne sont pas correctes, complètes, à jour ou pertinentes par rapport à votre recherche. Il en va de même pour toutes les autres pages de ce site. Veillez à vérifier les informations auprès des sources officielles de l'EPFL.

Publications associées (25)

Publications associées

Chargement

Personnes associées (6)

Personnes associées

Chargement

Unités associées (5)

Unités associées

Chargement

Concepts associés (10)

Concepts associés

Chargement

Cours associés (4)

Cours associés

Chargement

Séances de cours associées (6)

Séances de cours associées

Chargement

Effects of sectionning posterior cruciate ligament and its reconstruction with autograft and synthetic graft on the biomechanics of the knee

Alexandre Terrier

Gordon and Breach Pub2004

Chargement

Novel compartment-specific biosensors reveal a complementary subcellular distribution of bioactive Furin and PC7

Pierpaolo Ginefra

Proprotein Convertases (PCs) constitute a family of serine proteases that activate various hormones, growth factors and cell adhesion molecules by mediating endoproteolytic cleavage of their secreted inactive precursors during their transit in the secretory pathway. Their physiological roles in most tissues, in cancer and other diseases have remained nowadays poorly defined, partly because of technical hurdles in clearly distinguishing functionally overlapping PC activities from each other. Related to this, a major unsolved question is where, among the different subcellular compartments of the secretory pathway, substrate cleavage takes place. To address these questions, we mapped intracellular PC activities of two unrelated cell lines (HEK293T and B16F1 melanoma) by ratiometric and Förster Resonance Energy Transfer (FRET)-based imaging of the PC-specific biosensors, called cell-linked indicator of proteolysis (CLIP)v3 and CLIPv4 respectively, which are sorted to different subcellular compartments by specific trafficking signals. Until now, PCs have been thought to cleave the majority of the substrates in the trans-Golgi network (TGN). By contrast, our analysis of compartment-specific CLIPv3 and CLIPv4 variants in cultured cells suggested that PC activities are much higher in post-exocytic compartments. Furthermore, imaging in B16F1 Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-edited clones for endogenously expressed Furin or PC7, revealed an enrichment of Furin activity in endosomes compared to TGN, whereas PC7 activity was confined to a distinct compartment resistant to the pan-PC inhibitor CMK, demonstrating that endogenous Furin and PC7 are biologically active in distinct compartments. In addition, we also demonstrated that substrate and protease localization are rate-limiting of how efficiently a given substrate is processed. PC inhibition represses human primary melanoma cells motility and migration in vitro and proliferation in other skin cancer cells both in vitro and in vivo. To elucidate the roles of PC activities in melanoma progression and differentiation, we evaluated relative contribution of Furin and PC7 in B16F1 tumor grafts. Both proteins were required for tumor pigmentation, whereas Furin deletion reduced tumor growth, but its loss may be rescued by PC7 deletion. Altogether, these findings will be important to inform future therapeutic approaches and strategies for targeting PCs to preferentially block oncogenic activities.

EPFL2018

Chargement

Several treatments have been developed for treating bone fractures as they are very common events. Amongst other new strategies, synthetic bone substitutes present a very high potential therapy because they lower the risk of infection and rejection. Moreover, bone progenitor cells have been added to these bone graft substitutes, allowing them to gain the property of osteogenesis. Surprisingly, it has been observed that bone formation was less efficient in the case of bone substitutes seeded with bone progenitor cells compared to cell-free bone substitutes. This result raised questions about the evolution of these cells inside the implant. In order to investigate this shortcoming, osteoprogenitor cells have been transfected using a GFP lentivirus. Using a viability assay and Alizarin and ALP stainings, the characterization of GFP-transfected bone progenitor cells demonstrated a phenotype unaltered after transfection with a lentivirus.

2015

Chargement

Novel compartment-specific biosensors reveal a complementary subcellular distribution of bioactive Furin and PC7

Pierpaolo Ginefra

EPFL2018